IOVA - Iovance Biotherapeutics - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

IOVA is currently covered by 14 analysts with an average price target of $12.82. This is a potential upside of $11.16 (672.29%) from yesterday's end of day stock price of $1.66.

Iovance Biotherapeutics's activity chart (see below) currently has 195 price targets and 195 ratings on display. The stock rating distribution of IOVA is 91.55% BUY and 8.45% HOLD.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 44.75% with an average time for these price targets to be met of 178.25 days.

Highest price target for IOVA is $25, Lowest price target is $5, average price target is $18.7.

Most recent stock forecast was given by GEULAH LIVSHITS from CHARDAN CAPITAL on 08-May-2025. First documented stock forecast 02-Aug-2017.

Currently out of the existing stock ratings of IOVA, 65 are a BUY (91.55%), 6 are a HOLD (8.45%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$25

$23.25 (1328.57%)

$30

8 days ago
(08-May-2025)

3/16 (18.75%)

$23.25 (1328.57%)

137

Buy

$23

8 days ago
(08-May-2025)

2/11 (18.18%)

$15.03 (188.58%)

54

Buy

$20

$18.25 (1042.86%)

$32

8 days ago
(08-May-2025)

9/31 (29.03%)

$18.25 (1042.86%)

279

Buy

$16

$14.25 (814.29%)

$19

1 months ago
(16-Apr-2025)

1/5 (20%)

$12.94 (422.88%)

92

Buy

$5

$3.25 (185.71%)

$22

1 months 3 days ago
(13-Apr-2025)

3/8 (37.5%)

$1.59 (46.63%)

105

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is IOVA (Iovance Biotherapeutics) average time for price targets to be met?

On average it took 178.25 days on average for the stock forecasts to be realized with a an average price target met ratio 44.75

Which analyst has the current highest performing score on IOVA (Iovance Biotherapeutics) with a proven track record?

GEULAH LIVSHITS

Which analyst has the most public recommendations on IOVA (Iovance Biotherapeutics)?

Geulah Livshits works at CHARDAN CAPITAL and has 26 price targets and 14 ratings on IOVA

Which analyst is the currently most bullish on IOVA (Iovance Biotherapeutics)?

Biren Amin with highest potential upside - $41.25

Which analyst is the currently most reserved on IOVA (Iovance Biotherapeutics)?

Benjamin Burnett with lowest potential downside - -$0

Iovance Biotherapeutics in the News

Why Iovance Biotherapeutics Stock Is Crashing Today

Key Points Iovance’s Q1 revenue was sharply lower than expected. The company blamed the miss on lower production capacity due to annual maintenance at its cell therapy facility. However, Iovance’s full-year revenue guidance cut hints at a deeper problem. 10 stocks we like better than Iovance Biotherapeutics › Shares of Iovance Biotherapeutics(NASDAQ: IOVA) were crashing...

Iovance Biotherapeutics Reports Financial Results and Corporate Updates for First Quarter 2025

1Q25 Total Product Revenue of $49.3M FY25 Total Product Revenue Guidance Revised to $250M-$300M FY25 Operating Expenses Reduced and 2H26 Cash Runway Guidance Maintained 2025 Regulatory Approvals for Amtagvi® Expected in the UK, EU, and Canada On Track to Report Updated Clinical Data for Registrational Trial in Previously Treated Advanced NSCLC in 2H25 SAN CARLOS,...
Show more

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?